A017180 Stock Overview
Engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
MYUNGMOON Pharm co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,886.00 |
| 52 Week High | ₩2,970.00 |
| 52 Week Low | ₩1,820.00 |
| Beta | 0.14 |
| 11 Month Change | -15.05% |
| 3 Month Change | -18.71% |
| 1 Year Change | -15.24% |
| 33 Year Change | -60.13% |
| 5 Year Change | -60.13% |
| Change since IPO | -38.51% |
Recent News & Updates
Is MYUNGMOON PharmLtd (KRX:017180) Weighed On By Its Debt Load?
Sep 06
MYUNGMOON Pharm co.,Ltd's (KRX:017180) 35% Share Price Surge Not Quite Adding Up
Jul 26Recent updates
Is MYUNGMOON PharmLtd (KRX:017180) Weighed On By Its Debt Load?
Sep 06MYUNGMOON Pharm co.,Ltd's (KRX:017180) 35% Share Price Surge Not Quite Adding Up
Jul 26MYUNGMOON PharmLtd (KRX:017180) Has No Shortage Of Debt
Mar 21Does MYUNGMOON PharmLtd (KRX:017180) Have A Healthy Balance Sheet?
Mar 31Introducing MYUNGMOON PharmLtd (KRX:017180), A Stock That Climbed 77% In The Last Five Years
Feb 06
Does Myungmoon Pharm (KRX:017180) Have A Healthy Balance Sheet?
Dec 15Shareholder Returns
| A017180 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 0.1% | -3.1% | 2.9% |
| 1Y | -15.2% | 4.8% | -2.8% |
Return vs Industry: A017180 underperformed the KR Pharmaceuticals industry which returned 4.8% over the past year.
Return vs Market: A017180 underperformed the KR Market which returned -2.8% over the past year.
Price Volatility
| A017180 volatility | |
|---|---|
| A017180 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A017180 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A017180's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 281 | Kyu-Huok Lee | www.mmpharm.co.kr |
MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervous system products, female hormone products, osteoporotic therapeutics, urogentital agents, adrenocortical hormone products, oncology agents, other preparations, and anti-obesity agents for pharmacotherapy. The company also provides OTC products, such as antinausants, genitourinary system products, anti gum disease products, hepatics, parasiticides, cathartic, antidiarrheal agents, digestive system products, multiple vitamin products, eye nutrition products, eye drops, blood circulation products, circulatory solvents, skin external preparations, and topical analgesic products.
MYUNGMOON Pharm co.,Ltd Fundamentals Summary
| A017180 fundamental statistics | |
|---|---|
| Market cap | ₩63.23b |
| Earnings (TTM) | -₩7.72b |
| Revenue (TTM) | ₩176.37b |
0.4x
P/S Ratio-8.2x
P/E RatioIs A017180 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A017180 income statement (TTM) | |
|---|---|
| Revenue | ₩176.37b |
| Cost of Revenue | ₩78.38b |
| Gross Profit | ₩97.99b |
| Other Expenses | ₩105.71b |
| Earnings | -₩7.72b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -230.23 |
| Gross Margin | 55.56% |
| Net Profit Margin | -4.38% |
| Debt/Equity Ratio | 107.7% |
How did A017180 perform over the long term?
See historical performance and comparison